Sign up to save your podcasts
Or
Share Superblood: The Development of Novel Red-Cell Therapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Superblood: The Development of Novel Red-Cell Therapeutics
In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics.
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
View all episodes
By Peter Hofland
3
22 ratings
In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics.
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.